Vaccine scientists ‘on verge of antibody treatment for most vulnerable’

Scientists working on a potential coronavirus vaccine have nearly reached a breakthrough
REUTERS
Charlie Duffield7 June 2020

Scientists working on a potential coronavirus vaccine have nearly reached a breakthrough on an antibody treatment which could save the lives of the vulnerable and elderly.

According to British-Swedish pharmaceutical company AstraZeneca, an injection of cloned antibodies which allows the body to counteract Covid-19 has the potential to be hugely significant for those in the early stages of infection.

The company has already started to manufacture the Oxford University Covid-19 vaccine to make sure that, if it passes human trials, it can be made available in the autumn.

On Thursday, AstraZeneca signed a deal with the Coalition for Epidemic Preparedness Innovations (Cepi) to help manufacture 300 million globally accessible doses of the coronavirus vaccine candidate being developed by the Jenner Institute at the University of Oxford.

One member of the coalition is the Serum Institute of India, which The Sunday Telegraph reports is considering other “parallel” partnerships with AstraZeneca that could lead to the antibody treatment being funded as a stand-alone treatment.

AstraZeneca’s chief executive Pascal Soriot told the newspaper that the treatment being developed is “a combination of two antibodies” in an injected dose “because by having both you reduce the chance of resistance developing to one antibody”.

Antibody therapy is more expensive than vaccine production, with Mr Soriot saying the former would be prioritised for the elderly and vulnerable “who may not be able to develop a good response to a vaccine”.

It comes as trials of the potential vaccine have started in Brazil, a new epicentre of the pandemic, to ensure the study can be properly tested as transmission rates fall in the UK.

The Jenner Institute and the Oxford Vaccine Group began development on a vaccine in January, using a virus taken from chimpanzees.

Meanwhile, UK-based vaccine manufacturer Seqirus announced it is working in partnership with parent company CSL, CEPI and the University of Queensland to help develop a candidate Covid-19 vaccine in Australia.

Its manufacturing base in Liverpool is producing an adjuvant, an agent which improves the immune response of a vaccine.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in